Navigation Links
Aratana Therapeutics to Present at Two Upcoming Investor Conferences
Date:11/19/2013

KANSAS CITY, Kan. and BOSTON, Nov. 19, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it will present at the Jefferies 2013 London Healthcare Conference, to be held November 20-21, 2013, in London, UK, and at the Piper Jaffray 25th Annual Healthcare Conference, to be held December 3-4, 2013, at The New York Palace Hotel in New York.

Steven St. Peter, M.D., President and Chief Executive Officer, will provide an overview of the Company's business during his live presentations and will be available to participate in one-on-one meetings with investors who are registered to attend the conferences. 

Event:Jefferies 2013 London Healthcare ConferenceDate: Thursday, November 21, 2013 Time: 10:00 am (Greenwich Mean Time) Location:London, UK 

Event:Piper Jaffray 25th Annual Healthcare ConferenceDate: Wednesday, December 4, 2013 Time: 1:30 pm (Eastern Time)Location:New York, NY

The presentations will be webcast live and remain available for two weeks following the presentation.  To access the webcasts, please visit the investor relations section of the Aratana website at aratana.investorroom.com.

About Aratana Therapeutics
Aratana Therapeutics is a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner.  Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Contacts: 

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664

Andrew Mielach (media)
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
2. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
3. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
4. Aratana Therapeutics Adds To Drug Development Team
5. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
6. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
7. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
8. Aratana Therapeutics Completes $15 Million Series B Financing
9. Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
10. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
11. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):